Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CXCL13 is a plasma biomarker of germinal center activity.
Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, Bélanger S, Kasturi SP, Landais E, Akondy RS, McGuire HM, Bothwell M, Vagefi PA, Scully E; IAVI Protocol C Principal Investigators; Tomaras GD, Davis MM, Poignard P, Ahmed R, Walker BD, Pulendran B, McElrath MJ, Kaufmann DE, Crotty S. Havenar-Daughton C, et al. Among authors: tomaras gd. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7. doi: 10.1073/pnas.1520112113. Epub 2016 Feb 23. Proc Natl Acad Sci U S A. 2016. PMID: 26908875 Free PMC article.
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G. Betts MR, et al. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4512-7. doi: 10.1073/pnas.0408773102. Epub 2005 Mar 7. Proc Natl Acad Sci U S A. 2005. PMID: 15753288 Free PMC article.
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Russell ND, et al. Among authors: tomaras gd. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12. doi: 10.1097/01.qai.0000248356.48501.ff. J Acquir Immune Defic Syndr. 2007. PMID: 17106277 Free PMC article. Clinical Trial.
Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
Shen X, Dennison SM, Liu P, Gao F, Jaeger F, Montefiori DC, Verkoczy L, Haynes BF, Alam SM, Tomaras GD. Shen X, et al. Among authors: tomaras gd. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5972-7. doi: 10.1073/pnas.0912381107. Epub 2010 Mar 15. Proc Natl Acad Sci U S A. 2010. PMID: 20231447 Free PMC article.
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network. Peiperl L, et al. Among authors: tomaras gd. PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579. PLoS One. 2010. PMID: 21048953 Free PMC article. Clinical Trial.
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID. Spearman P, et al. Among authors: tomaras gd. J Infect Dis. 2011 Apr 15;203(8):1165-73. doi: 10.1093/infdis/jiq175. J Infect Dis. 2011. PMID: 21451004 Free PMC article. Clinical Trial.
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.
Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban M, Park CG, Trumpfheller C, Keler T, Pantaleo G, Steinman RM, Seder R. Flynn BJ, et al. Among authors: tomaras gd. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7131-6. doi: 10.1073/pnas.1103869108. Epub 2011 Apr 5. Proc Natl Acad Sci U S A. 2011. PMID: 21467219 Free PMC article.
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.
De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. De Rosa SC, et al. Among authors: tomaras gd. J Immunol. 2011 Sep 15;187(6):3391-401. doi: 10.4049/jimmunol.1101421. Epub 2011 Aug 15. J Immunol. 2011. PMID: 21844392 Free PMC article. Clinical Trial.
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC, McElrath MJ, Saavedra L, Lau CY, Graham BS; NIAID HIV Vaccine Trials Network. Koblin BA, et al. Among authors: tomaras gd. PLoS One. 2011;6(9):e24517. doi: 10.1371/journal.pone.0024517. Epub 2011 Sep 12. PLoS One. 2011. PMID: 21931737 Free PMC article. Clinical Trial.
391 results